Closing Insights: The Future of Cemiplimab in NSCLC and Beyond

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung cancer biomarker subtypes.

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.

Findings mark the first time a neoadjuvant immunotherapy regimen has demonstrated a significant survival benefit in a randomized phase 3 trial of a solid tumor.

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes